Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2025-02-24 Regulatory Filings
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Zawarcie umowy na doradztwo strategiczne ws. rejestracji terapii TREGS w Stanach Zjednoczonych
Regulatory Filings Classification · 100% confidence The document text, written in Polish, announces that the Management Board of PolTREG S.A. signed an agreement with Kinexum Services LLC for strategic consulting regarding the registration of the TREGS therapy with the US Food and Drug Administration (FDA). This involves preparing for a pre-IND meeting with the FDA and subsequent IND filing. This clearly relates to regulatory processes, clinical trials, and market entry strategy concerning a drug therapy. This type of announcement, detailing significant legal/regulatory steps for a product, best fits the 'Legal Proceedings Report' (LTR) category if it were a lawsuit, but since it is about regulatory approval processes and strategic engagement with a regulatory body (FDA), it is a significant corporate event related to product development and market access. Given the options, it is a specific regulatory/legal development concerning the product pipeline. Since there is no specific category for 'Regulatory Approval Strategy,' and it details a significant agreement impacting future operations and regulatory compliance, it is closest to a Legal/Regulatory Update. However, looking closely at the definitions, it is not a lawsuit (LTR) or a general regulatory filing (RNS). It is a strategic business development concerning regulatory pathways. If this were a US filer, it might be part of an 8-K Item 1.01 (Entry into a Material Definitive Agreement) or Item 7.01 (Regulation FD Disclosure). In the context of the provided codes, the most fitting category for a significant strategic agreement focused on regulatory compliance and market entry, which is not explicitly covered by M&A (TAR) or Financing (CAP), is often captured under general regulatory updates or significant corporate events. Since the core of the announcement is the engagement with the FDA for registration, and it is a material event, it is a significant corporate disclosure. Given the options, and noting that it is a specific update on a material agreement impacting regulatory status, it is a significant corporate event. Since it is not a standard financial report, dividend, or management change, and it details a strategic move impacting regulatory status, it is best classified as a Regulatory Filing (RNS) as a catch-all for material, non-standard disclosures, or potentially LTR if interpreted broadly as regulatory action, but RNS is safer for material announcements not fitting other specific codes. Given the document length is short (1559 chars) and it details a material agreement and future steps, it is a direct announcement of a material event, not an announcement *of* a report. I will classify it as RNS (Regulatory Filings) as the most appropriate general category for material, non-financial, non-governance specific announcements.
2025-02-24 Polish
Informacja nt. rekomendowania przez Agencję Badań Medycznych dofinansowania projektu badawczo-rozwojowego PolTREG S.A. - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a short announcement (1185 characters) from Zarząd PolTREG S.A. informing the market about a significant event: their project regarding Treg lymphocytes for Type 1 Diabetes treatment was placed on the ranking list for funding by the Medical Research Agency (ABM). It details the project value (8.3 million PLN) and the expected funding amount (6.4 million PLN). This is a material event concerning potential financing or a significant operational development, but it is not the final financing agreement itself, nor is it a standard earnings release or annual report. Since it announces a specific development related to funding/grants, the most appropriate category is 'Capital/Financing Update' (CAP), as it relates to securing significant external funding for a project. It is not a general regulatory filing (RNS) because it fits the specific definition of CAP better, even though it is an announcement.
2025-02-07 Polish
Informacja nt. rekomendowania przez Agencję Badań Medycznych dofinansowania projektu badawczo-rozwojowego PolTREG S.A.
Regulatory Filings Classification · 100% confidence The document is a formal announcement by the Management Board (Zarząd) of PolTREG S.A. regarding a significant event. The event is the inclusion of a project proposal ("Badania przedkliniczne antygenowo-specyficznych limfocytów Tregs...") on the ranking list of the Medical Research Agency (ABM) for funding. This concerns the company's research and development activities and potential financing/grants related to a specific therapeutic project. This type of announcement, detailing a significant development in R&D funding or project status, best fits the 'Capital/Financing Update' (CAP) category, as it relates to securing funding/grants for a major project, even if it's not traditional debt/equity financing. It is not a standard earnings release (ER), interim report (IR), or a general regulatory filing (RNS), as it describes a specific, material business development related to capital/project funding.
2025-02-06 Polish
Harmonogram publikacji raportów okresowych w 2025 roku - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text explicitly states that the Management Board ('Zarząd') is announcing the dates ('daty przekazywania') for the release of periodic reports (quarterly, semi-annual, and annual reports) for the year 2025, citing Polish financial regulations (§ 80 ust. 1 Rozporządzenia Ministra Finansów). This is not the report itself, but an announcement about when future reports will be published. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2025-01-24 Polish
Informacja nt. rekomendowania przez Polską Agencję Rozwoju Przedsiębiorczości dofinansowania projektu badawczo-rozwojowego PolTREG S.A. - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document is a brief announcement (1440 characters) from a Polish company (PolTREG S.A.) regarding the selection of its project for funding from the Polish Agency for Enterprise Development (PARP). It details the project scope (cell therapy for multiple sclerosis), total cost (85.7 million PLN), and the grant amount (51.4 million PLN). Crucially, the final paragraph states: "O zawarciu umowy dotyczącej dofinansowania jak również o innych istotnych zdarzeniach odnoszących się do realizacji projektu objętego dofinansowaniem Emitent będzie informował w trybie właściwych raportów" (The Issuer will inform about the conclusion of the co-financing agreement as well as other significant events related to the implementation of the co-financed project in the form of appropriate reports). This structure—announcing a significant event (funding approval) and promising future reports—fits the definition of a general regulatory announcement or a specific update that doesn't fit other categories like ER, IR, or CAP, but is more specific than a generic RNS. However, since it is a specific update about financing/grant approval, 'Capital/Financing Update' (CAP) is a strong candidate. Given the context of regulatory filings in Poland, this is a 'Raport Bieżący' (Current Report). Since it details a significant financing/grant approval, CAP is the most specific fit among the provided options, although RNS is a possible fallback if CAP is deemed too broad. Given the content is purely about securing funding/grant for a project, CAP is selected over the generic RNS.
2025-01-20 Polish
Rezygnacja z funkcji Członka Zarządu PolTREG S.A. - Content (PL)
Board/Management Information Classification · 99% confidence The document text, written in Polish, announces the resignation of Ms. Paulina Kocenko-Merks from the Management Board (Zarząd) of PolTREG S.A., effective immediately (20.01.2025), and the termination of her role as Financial Director, which will continue until 14.02.2025. This content directly relates to changes in senior management personnel. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2025-01-20 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.